Bluefish completes directed new share issue - provides SEK 40 million

Bluefish Pharmaceuticals AB (Bluefish) has completed a directed new share issue to Nexttobe AB (nxt2b) equivalent to SEK 40 million. After the new share issue, nxt2b will hold 15.7% of the capital and votes in Bluefish.

nxt2b is a privately owned investment company that was founded in 2011 by the Swedish entrepreneur Bengt Ågerup.

”nxt2b has extensive experience from the pharmaceutical industry and we look forward to a close collaboration”, says Karl Karlsson, CEO and founder of Bluefish.

The directed new share issue was carried out with deviation from the shareholders' preferential rights and in accordance with the Annual General Meeting's resolution on June 10, 2011, to authorize the Board of Directors in Bluefish to, at one or several occasions until the next AGM, issue new shares.  Through the share issue, the number of shares in Bluefish is increased by 6 666 667 and the share capital is increased by SEK 1 333 333. After the share issue, the company's share capital totals SEK 8 472 944 and the number of shares totals 42 364 720. The subscription price was SEK 6 for each new share.

The directed new share issue, together with the company’s new credit facility with SEB, strengthens Bluefish financial position and enables continued strong growth.

"Bluefish offers exciting business opportunities within the growing generics industry. nxt2b has a broad investment portfolio within the life science area and views the investment in Bluefish as an excellent complement ", says Bengt Ågerup.

For more information contact,

Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 20
Email: karl.karlsson@bluefishpharma.com

Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 21
Email: susanna.urdmark@bluefishpharma.com

Erika Kjellberg Eriksson, Partner nxt2b 
Tel. 46 76 117 18 23